/ Print /

PHARMACY BEST PRACTICES

Cardiovascular drugs: Current spending, future outlookCardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.
Pharma coupons: pros and consDrug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.
Novartis signs on to value-based pricing for EntrestoHospitalizations represent up to 80 percent of the direct medical costs of heart failure; reducing heart failure hospitalizations can help bring down overall healthcare costs.
Impact of Medicare's expanded benzodiazepine coverageLike any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications—just a year after Medicare Part D extended its coverage to include them in 2012—has some wondering why so many of these drugs are being prescribed.
Electronic prior authorization and payers: Lessons from BCBSTwo presenters at the AMCP 2016 conference examine a Blue Cross and Blue Shield of Michigan pilot project to leverage technology for its medical specialty drug management program. Here are the lessons learned.
High-cost generic programs decrease drug spend in 5 plansAMCP 2016 conference presenters from MedImpact outline their High-Cost Generic program that moves members to less-expensive, clinically relevant drug alternatives.
Predictions for the future of high-cost specialty drugsIMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.
Four new oncology payment modelsF. Randy Vogenberg, PhD, partner, Access Market Intelligence, and cofounder National Institute of Collaborative Healthcare, Greenville, S.C., shares insight from AMCP.
Pharmacists critical to success in 5 value-based modelsAt AMCP 2016, presenters identified five types of alternative payment models, and shared why pharmacists play a key role.
Five policy options to remedy value-based pricingValue-based pricing raises concerns when it comes to drug affordability and experts discuss a call to action saying “prices no longer reflect costs.”